NASDAQ:SPPI Spectrum Pharmaceuticals (SPPI) Stock Forecast, Price & News $1.07 -0.03 (-2.73%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$1.06▼$1.1250-Day Range$0.65▼$1.3152-Week Range$0.32▼$1.57Volume880,343 shsAverage Volume2.21 million shsMarket Capitalization$219.63 millionP/E RatioN/ADividend YieldN/APrice Target$2.44 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Spectrum Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside127.8% Upside$2.44 Price TargetShort InterestHealthy1.50% of Shares Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.84Based on 11 Articles This WeekInsider TradingSelling Shares$63,412 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.15) to $0.04 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.29 out of 5 starsMedical Sector261st out of 1,006 stocksPharmaceutical Preparations Industry120th out of 492 stocks 3.0 Analyst's Opinion Consensus RatingSpectrum Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 5 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $2.44, Spectrum Pharmaceuticals has a forecasted upside of 127.8% from its current price of $1.07.Amount of Analyst CoverageSpectrum Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.50% of the outstanding shares of Spectrum Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSpectrum Pharmaceuticals has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Spectrum Pharmaceuticals has recently decreased by 49.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSpectrum Pharmaceuticals does not currently pay a dividend.Dividend GrowthSpectrum Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreSpectrum Pharmaceuticals has received a 74.89% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Spectrum Pharmaceuticals is -0.75. Previous Next 2.1 News and Social Media Coverage News SentimentSpectrum Pharmaceuticals has a news sentiment score of 0.84. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for Spectrum Pharmaceuticals this week, compared to 3 articles on an average week.Search InterestOnly 5 people have searched for SPPI on MarketBeat in the last 30 days. This is a decrease of -85% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Spectrum Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -78% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Spectrum Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $63,412.00 in company stock.Percentage Held by InsidersOnly 2.70% of the stock of Spectrum Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 27.95% of the stock of Spectrum Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Spectrum Pharmaceuticals are expected to grow in the coming year, from ($0.15) to $0.04 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Spectrum Pharmaceuticals is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Spectrum Pharmaceuticals is -2.97, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSpectrum Pharmaceuticals has a P/B Ratio of 8.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Spectrum Pharmaceuticals (NASDAQ:SPPI) StockSpectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. Its product pipeline includes: Eflapegrastim, Poziotinib, and IGN002. The company was founded in December 1987 and is headquartered in Boston, MA.Read More Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPPI Stock News HeadlinesMay 31, 2023 | americanbankingnews.comSpectrum Pharmaceuticals, Inc. to Post Q3 2023 Earnings of $0.01 Per Share, HC Wainwright Forecasts (NASDAQ:SPPI)May 30, 2023 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Now Covered by StockNews.comJune 1, 2023 | UNKNOWN (Ad)World-Renowned Brazilian Restaurant Debuts in CanadaInvest in Debut's Exclusive Franchise of Acclaimed Brazilian Churrasco Restaurant Brand.May 26, 2023 | msn.comHC Wainwright & Co. Reiterates Spectrum Pharmaceuticals (SPPI) Neutral RecommendationMay 22, 2023 | americanbankingnews.comSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Receives $0.88 Average Price Target from AnalystsMay 17, 2023 | finance.yahoo.comSpectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementMay 15, 2023 | msn.comJefferies Downgrades Spectrum Pharmaceuticals (SPPI)May 15, 2023 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Downgraded to "Hold" at Jefferies Financial GroupJune 1, 2023 | UNKNOWN (Ad)Highly Profitable Restaurant Brand Expands to CanadaInvest in the Canadian Expansion with Debut: The Exclusive Franchisee with Proven Success.May 14, 2023 | finance.yahoo.comNews Flash: Analysts Just Made A Captivating Upgrade To Their Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) ForecastsMay 14, 2023 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Receives New Coverage from Analysts at StockNews.comMay 10, 2023 | finance.yahoo.comQ1 2023 Assertio Holdings Inc Earnings CallMay 9, 2023 | msn.comSpectrum Pharmaceuticals rises as co. says its Q1 net sales up 54% Q/QMay 9, 2023 | finance.yahoo.comSpectrum Pharmaceuticals (SPPI) Reports Q1 Loss, Tops Revenue EstimatesMay 6, 2023 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Research Coverage Started at StockNews.comMay 5, 2023 | markets.businessinsider.comB.Riley Financial Remains a Hold on Spectrum Pharmaceuticals (SPPI)May 1, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Reminds SPPI, NATI, CCFN, and ARST Shareholders About Its Ongoing InvestigationsApril 30, 2023 | benzinga.comLifshitz Law PLLC Announces Investigations of HOTH, ASRT, SPPI, and CEIApril 29, 2023 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Downgraded to Neutral at HC WainwrightApril 28, 2023 | benzinga.comMoore Kuehn Encourages HOTH, HSKA, SPPI, and GLOP Investors to Contact Law FirmApril 28, 2023 | americanbankingnews.comBrokers Offer Predictions for Spectrum Pharmaceuticals, Inc.'s Q2 2023 Earnings (NASDAQ:SPPI)April 27, 2023 | benzinga.comSHAREHOLDER ALERT: Weiss Law Investigates Spectrum Pharmaceuticals, Inc.April 27, 2023 | benzinga.comSpectrum Pharmaceuticals Stock (NASDAQ:SPPI), Short Interest ReportApril 27, 2023 | americanbankingnews.comSpectrum Pharmaceuticals (NASDAQ:SPPI) Downgraded by JMP Securities to Market PerformApril 26, 2023 | benzinga.comSHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Spectrum Pharmaceuticals, Inc. BuyoutApril 26, 2023 | markets.businessinsider.comExpert Ratings for Spectrum PharmaApril 26, 2023 | msn.comHC Wainwright & Co. Downgrades Spectrum Pharmaceuticals (SPPI)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SPPI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Spectrum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SPPI Company Calendar Last Earnings3/22/2023Today5/31/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SPPI CUSIP84763A10 CIK831547 Webwww.sppirx.com Phone(617) 586-3900Fax702-260-7405Employees163Year Founded2002Price Target and Rating Average Stock Price Forecast$2.44 High Stock Price Forecast$4.00 Low Stock Price Forecast$0.75 Forecasted Upside/Downside+127.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75,400,000.00 Net MarginsN/A Pretax Margin-263.04% Return on Equity-218.44% Return on Assets-66.16% Debt Debt-to-Equity RatioN/A Current Ratio2.71 Quick Ratio2.38 Sales & Book Value Annual Sales$25.73 million Price / Sales8.54 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book8.23Miscellaneous Outstanding Shares205,262,000Free Float199,720,000Market Cap$219.63 million OptionableOptionable Beta2.23 Social Links Key ExecutivesThomas J. RigaPresident, Chief Executive Officer & DirectorNora E. BrennanChief Financial Officer & Executive Vice PresidentMichael A. GrabowChief Business Officer & Executive Vice PresidentKeith M. McGahanSecretary, Chief Legal Officer & Executive VPKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLVerastemNASDAQ:VSTMXOMANASDAQ:XOMAMerrimack PharmaceuticalsNASDAQ:MACKVanda PharmaceuticalsNASDAQ:VNDAView All CompetitorsInsiders & InstitutionsNora BrennanSold 32,387 sharesTotal: $35,625.70 ($1.10/share)Armistice Capital LLCSold 300,000 shares on 5/16/2023Ownership: 8.135%Geode Capital Management LLCBought 245,235 shares on 5/16/2023Ownership: 0.856%State Street CorpBought 101,500 shares on 5/16/2023Ownership: 0.329%Susquehanna International Group LLPBought 27,600 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions SPPI Stock - Frequently Asked Questions Should I buy or sell Spectrum Pharmaceuticals stock right now? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spectrum Pharmaceuticals in the last year. There are currently 5 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SPPI shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SPPI, but not buy additional shares or sell existing shares. View SPPI analyst ratings or view top-rated stocks. What is Spectrum Pharmaceuticals' stock price forecast for 2023? 5 analysts have issued 12 month target prices for Spectrum Pharmaceuticals' stock. Their SPPI share price forecasts range from $0.75 to $4.00. On average, they expect the company's share price to reach $2.44 in the next twelve months. This suggests a possible upside of 125.7% from the stock's current price. View analysts price targets for SPPI or view top-rated stocks among Wall Street analysts. How have SPPI shares performed in 2023? Spectrum Pharmaceuticals' stock was trading at $0.3685 at the beginning of the year. Since then, SPPI shares have increased by 193.1% and is now trading at $1.08. View the best growth stocks for 2023 here. Are investors shorting Spectrum Pharmaceuticals? Spectrum Pharmaceuticals saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 3,080,000 shares, a drop of 49.2% from the April 30th total of 6,060,000 shares. Based on an average daily volume of 2,290,000 shares, the short-interest ratio is presently 1.3 days. View Spectrum Pharmaceuticals' Short Interest. When is Spectrum Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our SPPI earnings forecast. How were Spectrum Pharmaceuticals' earnings last quarter? Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) posted its earnings results on Wednesday, March, 22nd. The biotechnology company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.03. The biotechnology company had revenue of $10.11 million for the quarter, compared to the consensus estimate of $9.60 million. What is Joseph Turgeon's approval rating as Spectrum Pharmaceuticals' CEO? 2 employees have rated Spectrum Pharmaceuticals Chief Executive Officer Joseph Turgeon on Glassdoor.com. Joseph Turgeon has an approval rating of 47% among the company's employees. This puts Joseph Turgeon in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Spectrum Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Spectrum Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Verastem (VSTM), Exelixis (EXEL), SCYNEXIS (SCYX), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), OPKO Health (OPK), Bausch Health Companies (BHC), Sorrento Therapeutics (SRNE) and Zynerba Pharmaceuticals (ZYNE). What is Spectrum Pharmaceuticals' stock symbol? Spectrum Pharmaceuticals trades on the NASDAQ under the ticker symbol "SPPI." Who are Spectrum Pharmaceuticals' major shareholders? Spectrum Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Armistice Capital LLC (8.14%), Acadian Asset Management LLC (1.81%), BlackRock Inc. (1.68%), Geode Capital Management LLC (0.86%), Sargent Investment Group LLC (0.54%) and Renaissance Technologies LLC (0.47%). Insiders that own company stock include Francois Lebel, Jeff L Vacirca, Joseph W Turgeon, Keith M Mcgahan, Kurt A Gustafson, Nora Brennan, Seth H Z Fischer, Thomas J Riga and William Ashton. View institutional ownership trends. How do I buy shares of Spectrum Pharmaceuticals? Shares of SPPI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Spectrum Pharmaceuticals' stock price today? One share of SPPI stock can currently be purchased for approximately $1.08. How much money does Spectrum Pharmaceuticals make? Spectrum Pharmaceuticals (NASDAQ:SPPI) has a market capitalization of $221.68 million and generates $25.73 million in revenue each year. The biotechnology company earns $-75,400,000.00 in net income (profit) each year or ($0.36) on an earnings per share basis. How many employees does Spectrum Pharmaceuticals have? The company employs 163 workers across the globe. How can I contact Spectrum Pharmaceuticals? Spectrum Pharmaceuticals' mailing address is 11500 SOUTH EASTERN AVENUE SUITE 240, HENDERSON NV, 89052. The official website for the company is www.sppirx.com. The biotechnology company can be reached via phone at (617) 586-3900, via email at ir@sppirx.com, or via fax at 702-260-7405. This page (NASDAQ:SPPI) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Spectrum Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.